Polymerase News and Research

RSS

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Roche announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.

5 Feb 2011

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

UNC scientists who study how cells repair damage from environmental factors like sunlight and cigarette smoke have discovered how a "chaperone" enzyme plays a key role in cells' ability to tolerate the DNA damage that leads to cancer and other diseases.

19 Jan 2011

Chicks that don’t pass on bird flu

Influenza from birds, commonly known as H5N1 avian flu, has killed at least 306 people during the past seven years and innumerable birds and poultry. Now a team of scientists in Britain have developed a way to breed poultry that are genetically resistant to H5N1 or any other avian flu virus. The study by Scientists from Cambridge and Edinburgh universities was reported in the Jan. 13 issue of Science.

13 Jan 2011

OraSure to introduce QuickFlu test for detection of type A and type B influenza

OraSure Technologies, announced today the impending launch of the OraSure QuickFlu Rapid Flu A+B Test, a U.S. Food and Drug and Administration approved in vitro rapid qualitative test for the detection of influenza type A and type B, including H1N1 viral infections.

11 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.

5 Jan 2011

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Celera Corporation today announced that it has submitted a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.

3 Jan 2011

Researchers study molecular mechanisms in early stages of IPN virus infection

Infectious pancreatic necrosis is a serious disease that leads to enormous losses in the salmon industry each year. The virus that causes the disease, IPN, is very prevalent in farmed salmon and trout in Norway. The virus attacks a wide diversity of hosts and has been found to occur in many different fish species, in addition to shellfish and molluscs.

30 Dec 2010

New nanoparticle-based diagnostic platform provides rapid detection of sepsis

Blood poisoning can be fatal. If you suffer from sepsis, you used to have to wait as much as 48 hours for laboratory findings. A new diagnostic platform as big as a credit card will now supply the analysis after as little as an hour. This system is based on nanoparticles that are automatically guided by magnetic forces.

22 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

New online tool helps scientists to find gene promoters

Researchers at The Wistar Institute announce the release of an online tool that will help scientists find "gene promoters"—regions along a DNA strand that tell a cell's transcription machinery where to start reading in order to create a particular protein.

22 Dec 2010

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.

14 Dec 2010

Scientists determine 500 three-dimensional protein structures from bacterial and protozoan pathogens

9 Dec 2010

Scientists work together to wipe out some of the most lethal diseases

Scientists at Seattle Biomedical Research Institute and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet. As leaders of two large structural genomics centers, they've experimentally determined 500 three-dimensional protein structures from a number of bacterial and protozoan pathogens, which could potentially lead to new drugs, vaccines and diagnostics to combat deadly infectious diseases.

8 Dec 2010

FDA grants 510(k) clearance to Focus Diagnostics Simplexa Flu A/B & RSV test on 3M Integrated Cycler

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Focus Diagnostics Simplexa Flu A/B & RSV test on the 3M™ Integrated Cycler. The Simplexa test, developed and manufactured by Quest Diagnostics' Focus Diagnostics business, is intended as an aid in the detection and discrimination of influenza A, influenza B and RSV virus infections.

From Quest Diagnostics 2 Dec 2010

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

24 Nov 2010

Alnylam presents data on RNAi technologies at MIT Center Summit

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new data at the MIT Center for Biomedical Innovation's Biomanufacturing Summit from its platform efforts aimed at developing RNAi technologies for applications in biologics manufacturing.

19 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

Nanotrope assay receives U.S. patent for diagnosing influenza and viral infections

Nanotrope, Inc. announced today that it has been issued United States patent #7,829,272 covering its ground-breaking diagnostic test for influenza and other viral infections.

17 Nov 2010

Polymerase News and Research

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

UNC scientists discover how chaperone enzyme plays a key role in cells' ability to tolerate DNA damage

Chicks that don’t pass on bird flu

OraSure to introduce QuickFlu test for detection of type A and type B influenza

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Celera seeks FDA premarketing approval for KIF6 Genotyping Assay

Researchers study molecular mechanisms in early stages of IPN virus infection

New nanoparticle-based diagnostic platform provides rapid detection of sepsis

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

New online tool helps scientists to find gene promoters

Pharmasset initiates dosing in PSI-7977 exploratory study in HCV

Scientists determine 500 three-dimensional protein structures from bacterial and protozoan pathogens

Scientists work together to wipe out some of the most lethal diseases

FDA grants 510(k) clearance to Focus Diagnostics Simplexa Flu A/B & RSV test on 3M Integrated Cycler

A new treatment landscape for triple-negative breast cancer

Alnylam presents data on RNAi technologies at MIT Center Summit

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Nanotrope assay receives U.S. patent for diagnosing influenza and viral infections

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News